|Articles|January 15, 2007
IND for iCo
iCo Therapeutics, an Isis Pharmaceuticals licensee, has filed an Investigational New Drug (IND) application with the FDA for iCo-007.
Advertisement
iCo Therapeutics, an Isis Pharmaceuticals licensee, has filed an Investigational New Drug (IND) application with the FDA for iCo-007.
iCo-007, for the treatment of eye diseases such as age-related macular degeneration and diabetic retinopathy, is a second generation drug that inhibits the production of c-Raf kinase, an enzyme associated with the development of new blood vessels in the eye.
Isis will receive a milestone payment from iCo based on the IND filing.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
2026 Nobel Prize in Physiology or Medicine awarded for optogenetics discovery
2
Oku Digital Health launches from Topcon to link eye care, primary care
3
EURETINA 2026: Optogenetic therapy MCO-010 aims to restore vision in advanced macular disease
4
EURETINA 2026: Eyestem interim Phase 2 results for clinical study of Eyecyte-RPE for GA secondary to dry AMD
5















